The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
24 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $4,986,582 in first-year total cost, median $202,703.
Most frequent study sections
- Special Emphasis Panel[ZAI1 LG-M (S1)]13
- Special Emphasis Panel[ZAI1 LG-M (S2)]11
Most frequent institutions
- BAYLOR COLLEGE OF MEDICINE2
- UNIVERSITY OF COLORADO2
- UNIVERSITY OF WISCONSIN-MADISON2
- AVIDBIOTICS CORPORATION1
- BOSTON UNIVERSITY MEDICAL CAMPUS1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2016 | Development of Modified R-type Bacteriocins to Specifically Target C. difficile and Prevent Relapse of CDIs1R21AI121692-01 | SCHOLL, DEAN M | AVIDBIOTICS CORPORATION, CA | $324,080 | ZAI1 |
| 2016 | Nanoparticle decoys for treating infections with enterotoxin-producing pathogens1R21AI121571-01 | ECKMANN, LARSZHANG, LIANGFANG | UNIVERSITY OF CALIFORNIA, SAN DIEGO, CA | $306,459 | ZAI1 |
| 2016 | Defined microbial communities for the treatment of recurrent C. difficile infection1R21AI121522-01 | BRITTON, ROBERT A | BAYLOR COLLEGE OF MEDICINE, TX | $237,827 | ZAI1 |
| 2016 | Development of therapeutic bacteriophages against carbapenemase-resistant Klebsiella pneumoniae1R21AI121689-01 | GILL, JASON J.WALSH, THOMAS | TEXAS A&M AGRILIFE RESEARCH, TX | $234,034 | ZAI1 |
| 2016 | Synergistic Photodynamic Therapy for Catherer-Associated Urinary Tract Infections1R21AI121700-01 | HAMBLIN, MICHAEL R | MASSACHUSETTS GENERAL HOSPITAL, MA | $233,488 | ZAI1 |
| 2016 | Therapeutic Potential of Cystatin 9 Treatment to Fight Bacterial Pneumonia1R21AI121604-01 | EAVES-PYLES, TONYIA D | UNIVERSITY OF TEXAS MED BR GALVESTON, TX | $230,963 | ZAI1 |
| 2016 | Bacteriophage to prevent infection by antibiotic-resistant enterococci1R21AI121552-01 | KRISTICH, CHRISTOPHER J | MEDICAL COLLEGE OF WISCONSIN, WI | $230,125 | ZAI1 |
| 2016 | Microbial-ecology guided discovery of non-traditional therapeutics that limit resistance1R21AI121704-01 | KWAN, JASON CHRISTOPHER | UNIVERSITY OF WISCONSIN-MADISON, WI | $224,200 | ZAI1 |
| 2016 | Development of the RNA molecule-enriched, cell type-specific exosomes1R21AI121644-01 | JIN, YANG | BOSTON UNIVERSITY MEDICAL CAMPUS, MA | $221,445 | ZAI1 |
| 2016 | Bacteriophage to treat UTI caused by multidrug-resistant P. aeruginosa1R21AI121545-01 | RAMIG, ROBERT FRANKLIN | BAYLOR COLLEGE OF MEDICINE, TX | $217,938 | ZAI1 |
| 2016 | Development of anti-virulence drugs by targeting the SaeRS two component system of Staphylococcus aureus1R21AI121664-01 | BAE, TAEOK | INDIANA UNIVERSITY INDIANAPOLIS, IN | $207,768 | ZAI1 |
| 2016 | A safe, targeted, designer probiotic to prevent or treat C. difficile infection1R21AI121590-01 | VEDANTAM, GAYATRI | UNIVERSITY OF ARIZONA, AZ | $204,916 | ZAI1 |
| 2016 | Polymeric Agents for the Treatment of Clostridium difficile Infections1R21AI121684-01 | GELLMAN, SAMUEL H.MCBRIDE, SHONNA M. | EMORY UNIVERSITY, GA | $200,490 | ZAI1 |
| 2016 | Development of HAMLET as a Adjuvant for the Treatment of Drug-resistant Staphylococcus Aureus Infections1R21AI121614-01 | EDWARDS, KATIE J.HAKANSSON, ANDERS PER | CUBRC, INC., NY | $198,948 | ZAI1 |
| 2016 | Towards the Development of Engineered Phage Therapeutics against MDR Pathogens1R21AI121531-01 | HUBBY, BOLYN | SYNTHETIC GENOMICS VACCINES, INC., CA | $198,106 | ZAI1 |
| 2016 | Small Molecule Inhibition of Pilus Biogenesis by Pathogenic Bacteria1R21AI121639-01 | THANASSI, DAVID G | STATE UNIVERSITY NEW YORK STONY BROOK, NY | $195,071 | ZAI1 |
| 2016 | Phage depolymerases as antibiotics1R21AI121685-01 | BULL, JAMES JMOLINEUX, IAN J | UNIVERSITY OF TEXAS AT AUSTIN, TX | $192,975 | ZAI1 |
| 2016 | Engineering “Phagebody” Antimicrobials for Carbapenem-Resistant Enterobacteriaceae1R21AI121669-01 | LU, TIMOTHY | MASSACHUSETTS INSTITUTE OF TECHNOLOGY, MA | $189,983 | ZAI1 |
| 2016 | A Novel Screen for Antibacterials that Are Non-Toxic to Mammals1R21AI121365-01 | DETWEILER, CORRELLA SWANG, XIANG | UNIVERSITY OF COLORADO, CO | $186,369 | ZAI1 |
| 2016 | Development of Novel Resistance-Modifying Agents for MRSA1R21AI121581-01 | WANG, XIANG | UNIVERSITY OF COLORADO, CO | $186,262 | ZAI1 |
| 2016 | A biotherapeutic CRISPR-delivery platform to eradicate Clostridium difficile1R21AI121662-01 | VAN PIJKEREN, JAN-PETER | UNIVERSITY OF WISCONSIN-MADISON, WI | $179,732 | ZAI1 |
| 2016 | Microbes that Matter: defining optimal formulations for Microbial Ecosystem Therapeutics1R21AI121575-01 | ALLEN-VERCOE, EMMAPETROF, ELAINE O | QUEEN'S UNIVERSITY AT KINGSTON, ON | $148,500 | ZAI1 |
| 2016 | Targeting Cell Membrane Adaptation in Multidrug-Resistant Enterococcus faecium1R21AI121519-01 | ARIAS, CESAR AUGUSTO | UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON, TX | $118,860 | ZAI1 |
| 2016 | Harnessing bacteriophages as natural predators to combat the superbugs: a pulmonary drug delivery approach1R21AI121627-01 | CHAN, KIM | UNIVERSITY OF SYDNEY | $118,043 | ZAI1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.